PMID- 22296372
OWN - NLM
STAT- MEDLINE
DCOM- 20120918
LR  - 20181201
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 12
IP  - 9
DP  - 2011
TI  - Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based 
      chemotherapy for advanced non small cell lung cancer.
PG  - 2291-4
AB  - OBJECTIVE: To evaluate the influence of multi-drug resistance 1 (MDR1) gene codon 
      3435 polymorphisms on response to platinum-based chemotherapeutic regimens for 
      advanced non small cell lung cancer (NSCLC). METHODS: Responses and overall 
      survival were evaluated in a series of patients presenting between March 1, 2005 
      and December 31, 2010. MDR1 gene C3435T polymorphisms were genotyped using 
      peripheral blood with real time polymerase chain reaction (RT-PCR) and 
      relationships between the MDR1 C3435T genetic polymorphism and response rate of 
      chemotherapy were analyzed by SPSS 13.0. RESULTS: Overall response to 
      chemotherapy in the eligible 103 patients was 21.4%. Patients with C/C genotype 
      in MDR1 codon 3435 had a significantly higher response rate (24.5%) than those 
      for C/T(19.0%) and T/T(12.5%) (P<0.05). The overall median survival time (MST) of 
      patients was 19 months, values with C/C, C/T and T/T genotype were 21, 15.5 and 
      17 months, respectively (P=0.487). CONCLUSION: Our research suggested that 
      patents with the C/C genotype in MDR1 codon 3435 could be more sensitive to 
      platinum-based chemotherapy than patients with C/T and T/T; however, no 
      significant difference was found between overall survival and MDR1 codon 3435 
      genetic polymorphisms.
FAU - Yan, Peng-wei
AU  - Yan PW
AD  - Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute, 
      Nanjing, China.
FAU - Huang, Xin-en
AU  - Huang XE
FAU - Yan, Feng
AU  - Yan F
FAU - Xu, Lin
AU  - Xu L
FAU - Jiang, Yong
AU  - Jiang Y
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (ABCB1 protein, human)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 1)
RN  - 0 (Codon)
RN  - 0 (Organoplatinum Compounds)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 1/*genetics
MH  - Adult
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/blood/*drug therapy/*genetics
MH  - *Codon
MH  - Drug Resistance, Multiple
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Lung Neoplasms/blood/*drug therapy/*genetics
MH  - Male
MH  - Middle Aged
MH  - Organoplatinum Compounds/*therapeutic use
MH  - Polymorphism, Genetic
MH  - Survival Rate
EDAT- 2012/02/03 06:00
MHDA- 2012/09/19 06:00
CRDT- 2012/02/03 06:00
PHST- 2012/02/03 06:00 [entrez]
PHST- 2012/02/03 06:00 [pubmed]
PHST- 2012/09/19 06:00 [medline]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2011;12(9):2291-4.